Stoke Therapeutics (STOK) Profit After Tax (QoQ) (2018 - 2026)

Stoke Therapeutics (STOK) Profit After Tax (QoQ) (2018 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,831.58 Bn 66,831.30 Bn -
2 Nanobiotix 1,916.61 Bn 1,916.55 Bn -
3 Akari Therapeutics 976.78 Bn 976.78 Bn -
4 BeOne Medicines 471.48 Bn 466.69 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.78 Bn 114.53 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn
7 Belite Bio 63.06 Bn 63.06 Bn -
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.54 Bn 34.53 Bn 959.66 Mn
10 Stoke Therapeutics 1.87 Bn 1.53 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 14.57%
Dec 31, 2025 -54.04%
Sep 30, 2025 -61.81%
Jun 30, 2025 -120.80%
Mar 31, 2025 1,177.33%
Dec 31, 2024 60.34%
Sep 30, 2024 -2.86%
Jun 30, 2024 2.57%
Mar 31, 2024 1.72%
Dec 31, 2023 -10.39%
Sep 30, 2023 20.70%
Jun 30, 2023 -35.97%
Mar 31, 2023 12.12%
Dec 31, 2022 1.75%
Sep 30, 2022 -5.92%
Jun 30, 2022 -0.01%
Mar 31, 2022 -0.82%
Dec 31, 2021 -8.19%
Sep 30, 2021 -2.87%
Jun 30, 2021 -30.81%